A B S T R A C T The effect of two prostaglandin synthesis inhibitors, indomethacin and meclofenamate, on angiotensin II (AII)-and III (AIII)-induced aldosterone release was studied in normal and sodiumdepleted conscious rats and in adrenal capsular cell suspensions obtained from normal rats. In normal rats, in vivo AII and AIII were equipotent in causing doserelated increases in serum aldosterone concentrations. Indomethacin decreased the basal serum aldosterone levels by 50% and serum renin levels by 43%. In addition, the steroidogenic effects of AII and AIII were reduced by 45 and 63% with 3 mg/kg of indomethacin and 63 and 73% with 10 mg/kg, respectively. In contrast, meclofenamate failed to alter basal serum levels of aldosterone or AII-stimulated aldosterone release but inhibited serum renin levels by 27% and the aldosterone-stimulating effect of AIII by 99%. Indomethacin (3 mg/kg) and meclofenamate (2 mg/kg) inhibited urinary prostaglandin (PG)E2 and PGF2G excretion by 63 1552 stimulated aldosterone release but inhibited that stimulated by AIII by 86%. The present findings suggest that prostaglandins modulate the effects of the renin-angiotensin system by stimulating the release of renin from the kidney and augmenting the steroidogenic effects of AII and AIII in the adrenal cortex.
INTRODUCTION
Recently, we have reported that both angiotensin II and III were equipotent in stimulating the release of aldosterone from the adrenal cortex; however, angiotensin III possessed only 30% of the pressor activity of angiotensin II (1, 2) . These peptides were found to release prostaglandin (PG)E from the perfused kidney and mesenteric arterial vasculature (3) (4) (5) . The released prostaglandins were vasodilators and antagonized the vasoconstriction caused by the angiotensins. Additionally, PGE stimulated the release of aldosterone from the adrenal, a property that was additive in effect with that of angiotensin II (6, 7) . We, therefore, wondered if angiotensin II and III might simultaneously stimulate the release of aldosterone and PGE2 from the adrenal, and the released PGE2, acting as an intra-adrenal hormone, would also stimulate the release of aldosterone, thereby augmenting angiotensin-induced steroidogenesis. To test this hypothesis, the steroidogenic activity of angiotensin II and III were compared in conscious rats and adrenal cell suspensions in the presence and absence of the inhibitors of prostaglandin synthesis, indomethacin and meclofenamate (8) .
Purina Co. Inc., St. Louis, Mo.) (150 meq Na/kg and 270 meq K/kg) and water ad lib. Sodium depletion was produced by placing the rats on a sodium-deficient diet containing 10 meq Na/kg and 220 meq K/kg (ICN Nutritional Biochemicals Div., Cleveland, Ohio) for 5 d and given furosemide 10 mg/kg i.p. the first 2 d of dietary alteration (2) .
Conscious rats. Chronic catheters were placed in the jugular vein ofrats 18-24 h before the experimental procedure (1, 2) . Subsequently, angiotensin II, III (Beckman Instruments, Inc., Fullerton, Calif.), or 5% dextrose (control) was infused intravenously at 50 ,1u/min for 20 min into the conscious rats. In the rats receiving the prostaglandin synthesis inhibitors, indomethacin (Sigma Chemical Co., St. Louis, Mo.) or meclofenamate (Parke-Davis & Co., Detroit, Mich.) suspended in olive oil were given subcutaneously 100 min before the infusion of the peptides. At the end of the infusion period, the animals were killed by decapitation and the aortic blood (4 ml) was collected in plastic tubes on ice. The serum was separated at 4°C and stored at -20°C until assayed for renin and aldosterone.
An additional set of animals was placed in metabolic cages to allow urine collection. After 3 d of equilibration, an 8-h urine sample was collected from 0800 to 1600. The urine was then filtered and stored at -20°C until assayed for prostaglandins. The following day the rats were given indomethacin (3 (9) . The column eluates were dried at 30°C with nitrogen, liquid scintillation fluid added, and counted in a Beckman liquid scintillation spectrometer (Beckman Instruments, Inc.).
Adrenal cell suspensions. Adrenal cell suspensions were prepared by the method of Sarstedt et al. (10) with several modifications. Rats were killed by decapitation, their adrenals removed, and the adrenals placed in potassium-free medium 199. The adrenals were separated from the adhering fat, and the capsules removed. The capsular tissue was minced and incubated in potassium-free medium 199 containing 0.5 mg/ml of trypsin (Sigma Chemical Co.) for 15 min in a Dubnoff metabolic shaker at 37°C under an atmosphere of 95% 02 and 5% CO2 at 60 rpm. The tissue was then washed twice with potassium-free medium 199 containing 2 mg/ml of bovine serum albumin and 1 mg/ml of lima bean trypsin inhibitor (Sigma Chemical Co.) The tissue was resuspended in medium 199 containing 1 mg/ml of collagenase (Worthington Biochemial Corp., Freehold, N. J.), 0.05 mg/ml of deoxyribonuclease (Sigma Chemical Co.), 0.05 mg/ml of ribonuclease (Sigma Chemical Co.), and 2 mg/ml of bovine serum albumin and incubated for 1 h in a Dubnoff metabolic shaker at 37°C under 95% 02 and 5% CO2 with 60 rpm agitation. After 30 and 60 min ofincubation, the cells were dispersed by repeated (30 times) pipetting. The suspension was then washed twice with potassium-free medium 199 containing 1 mg/ml of lima bean trypsin inhibitor and 2 mg/ml of bovine serum albumin and resuspended in medium 199 containing 4.5 meq/liter of potassium and 2 mg/ml of bovine serum albumin. The adrenal cells were counted with a hemocytometer and the number of viable cells determined by exclusion staining of tryptan blue. With this method, -300,000 viable cells are obtained per adrenal capsule, and the viability of the cells is -94%. 0.5 ml containing 500,000-700,000 cells was then incubated for 1 h in a Dubnoff metabolic shaker at 370C under an atmosphere of 95%02 and 5% CO2. All compounds were added in a constant volume of 10 ,ul and an equal volume of their vehicle was added to the control tubes. At the end of the incubation period, the cell suspensions were centrifuged and the supemate assayed for aldosterone by direct radioimmunoassay and in some cases PGE2. The results were expressed as nanograms ofaldosterone per 106 cells per hour.
Assays. Serum aldosterone concentrations were measured by radioimmunoassay, corrected for recoveries, and expressed as nanograms per deciliter (11) . Serum renin activity was measured by the antibody trapping method of Poulsen and Jorgensen (12) and the results expressed as nanograms of angiotensin I generated per milliliter of serum per hour. Finally, urinary and adrenal PGE2 and PGF2,, were measured by radioimmunoassay after acid-lipid extraction and silicic acid chromatography (9) . The PGE2 and PGF2a, antisera were produced in our laboratory in rabbits against a prostaglandinthyroglobulin conjugate according to the method of Jaffe and Behrnan (13) . The PGE2 antibody cross-reacted 50% with PGE1 and <0.5% with PGD2, PGF2,,, PGB2, PGA2, 6-ketoPGFi,e, and its 15-keto metabolites. The PGF2 antibody showed a 100% cross-reaction with PGF1,, and <0.5% crossreaction with PGD2, PGE2, PGB2, PGA2, 6-keto-PGF1,, and its 15-keto metabolites. Urinary PGE was also measured by bioassay (3) after acid-lipid extraction, purification by thin-layer chromatography, and bioassay employing the rat stomach fundic strip, rat colon, and chick rectum. When comparing groups, statistical analyses were performed with an analysis of variance and Student's t test (14) . When comparing dose-response curves, analysis ofcovariance. was used for statistical significance (14) and the 20% effective dose or concentrations giving a 20 ng/dl increase in serum aldosterone or 20 ng/106 cells/h increase in media aldosterone concentration was used to compare potency of peptides.
RESULTS
Conscious rats. The effect of indomethacin on urinary prostaglandin excretion rate is shown in Table I . During the 8-h period of urine collection, the excretion of PGE2 was 58.7±9.2 ng/8 h when measured by bioassay and 67.7+9.2 ngl8 h by radioimmunoassay. The urinary PGE2 excretion decreased by >60% after indomethacin as measured by both techniques. Similarly, the excretion of PGF20, was reduced by 52% (P < 0.001) after indomethacin. Meclofenamate reduced the urinary excretion of PGE2 and PGF2. by 37 and 31%, respectively. The effect of the prostaglandin synthesis inhibitors administered in vivo (Table III) . Indomethacin reduced the serum renin activity by 43% (P < 0.01), whereas meclofenamate caused a 27% reduction (P < 0.05). Fig. 1 illustrates the effect of indomethacin on angiotensin-induced aldosterone release. Angiotensin II and III were equipotent in stimulating a dose-related increase in serum aldosterone. Indomethacin reduced the control aldosterone levels from 2.4+0.3 ng/dl to 1.2+0.4 ng/dl (P < 0.02). Additionally, in similarly infused animals pretreated with indomethacin 3 mg/ kg, the steroidogenic responses to angiotensin II and III were reduced by 45 and 63%, respectively, as indicated by the shift in the dose-response curve to the right. Further reductions of the steroidogenic responses were achieved with a 10 mg/kg dose of indomethacin. This higher dose caused a 63 and 73% suppression of angiotensin II-and III-induced aldosterone release, respectively.
The effects of meclofenamate on angiotensin-induced steroidogenesis is shown in Fig. 2 . Unlike indomethacin, meclofenamate failed to alter the control or the angiotensin II-induced aldosterone release. However, the response to angiotensin III was inhibited by 99% (P < 0.001).
The effects of indomethacin were also tested in sodium-depleted rats (Fig. 3) . After sodium depletion, the control serum aldosterone levels increased from 2.4+0.3 to 74±6 ng/dl (P < 0.001), and serum renin activity increased from 3.1±0.3 to 12.1 ± 1.8 ng/ml per h (P <0.001). Indomethacin (3 mg/kg) decreased the serum aldosterone by 29% without altering the serum renin activity. Additionally, the response of serum aldosterone to angiotensin II was partially inhibited from 164±8 to 126±4 ng/dl (P < 0.05), whereas the response to angiotensin III was completely suppressed to a value identical to that observed with indomethacin alone (116±5 to 53± 10 ng/dl [P < 0.01]).
Adrenal cell suspensions. In adrenal cell suspensions, angiotensin II and III caused a dose-related increase in aldosterone release with angiotensin III being 53% as potent as angiotensin II (Figs. 4 and 5) . Indomethacin (1 ,ug/ml) decreased the basal aldosterone release by 29% and reduced the release ofPGE2 from 709+84 to 381±10 pg/1O6 cells per h. In addition, indomethacin inhibited the steroidogenic effects of angiotensin II and III by 81 and 93%, respectively (Fig. 4) . Unlike indomethacin, meclofenamate (1 ,ug/ml)failed to alter basal or angiotensin II-stimulated aldosterone release (Fig. 5) . However, angiotensin III-stimulated aldosterone release was inhibited by 86% by meclofenamate.
DISCUSSION
Recent studies have demonstrated that PGE, and PGE2 stimulate the release of aldosterone, whereas PGFI,Q and PGF20, in similar studies inhibit its release (6, 7). Additionally, the steroidogenic effect of PGE, was found to be additive with those of angiotensin II (6) , suggesting that a dual mechanism involving these two hormone systems may be operative in the control of aldosterone secretion.
A number of investigators have attempted to probe this prostaglandin-renin-angiotensin interaction by activating the renin-angiotensin component with furosemide while also inhibiting the prostaglandin component with prostaglandin synthesis inhibitors (15, 16) . In these studies, indomethacin inhibited the increase in aldosterone secretion caused by furosemide as well as the increase in renin. Similarly, in patients with hyperreninemia and hyperaldosteronism caused by Bartter's syndrome, prostaglandin synthesis inhibitors also decreased the plasma renin activity and the plasma aldosterone levels (17 (25) .
